摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-二甲基哌嗪-2-甲酸乙酯 | 90729-01-4

中文名称
1,4-二甲基哌嗪-2-甲酸乙酯
中文别名
——
英文名称
1,4-dimethyl-piperazine-2-carboxylic acid ethyl ester
英文别名
ethyl N,N'-dimethylpiperazine-2-carboxylate;1,4-Dimethyl-piperazin-carbonsaeure-(2)-aethylester;Ethyl 1,4-dimethylpiperazine-2-carboxylate
1,4-二甲基哌嗪-2-甲酸乙酯化学式
CAS
90729-01-4
化学式
C9H18N2O2
mdl
MFCD00173923
分子量
186.254
InChiKey
RRXUQLWWJFBPKT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    76-80°C
  • 密度:
    1.019±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    13
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    32.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34
  • 海关编码:
    2933599090
  • 危险品运输编号:
    UN 2735

SDS

SDS:6636932277276b101e51b63b8ebea4ac
查看
Name: Ethyl 1 4-dimethylpiperazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS: 90729-01-4
Section 1 - Chemical Product MSDS Name:Ethyl 1 4-dimethylpiperazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
90729-01-4 Ethyl 1,4-dimethylpiperazine-2-carboxy 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 90729-01-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 76 - 80 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H18N2O2
Molecular Weight: 186.25

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 90729-01-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1,4-dimethylpiperazine-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 90729-01-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 90729-01-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 90729-01-4 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    1,4-二甲基哌嗪-2-甲酸乙酯sodium hydroxide盐酸乙醚甲醇二氯甲烷 作用下, 以 乙醇 为溶剂, 反应 2.0h, 以to give pH4的产率得到1,4-二甲基哌嗪-2-羧酸
    参考文献:
    名称:
    HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS
    摘要:
    化合物的公式为(I)Q-L-W—C(═X)—Z—P,其中Q是公式—N(R1)(R2)的胺基;L是烷基或杂环烷基-烷基连接物;W是一个6-或7-成员的脂肪环,包括环原子Y1和Y2,它们分别与基团L和C(X)连接,并且Y1和Y2独立地选自N和C;X是O、N、N—CN或S;Z是NR3;P是可选取代的单环或双环芳基或杂芳基;以及其药学上可接受的盐或溶剂,用于治疗C-C趋化因子介导的疾病。
    公开号:
    US20140038978A1
  • 作为产物:
    描述:
    2,3-二溴丙酸乙酯N,N'-二甲基乙二胺三乙胺 作用下, 以 为溶剂, 反应 3.0h, 以25%的产率得到1,4-二甲基哌嗪-2-甲酸乙酯
    参考文献:
    名称:
    具有中心烟碱作用的N1-乙酰基-N4-二甲基-哌嗪碘化物(ADMP)和N1-苯基-N4-二甲基-哌嗪碘化物(DMPP)的杂交和等距类似物。
    摘要:
    通过将N1-乙酰基-N4-二甲基哌嗪碘化物(1,ADMP)和N1-苯基-N4-二甲基哌嗪碘化物(3,DMPP)或相应的叔碱基(2, 4)用槟榔碱(5)和槟榔酮(6)或通过等规取代DMPP的苯环。杂交提供了既作为叔碱又作为碘甲基化物的化合物,其对烟碱样受体没有亲和力。相反,等位取代使化合物对受体保持亲和力。其中,两个叔碱基(37、38)对烟碱样受体具有纳摩尔级的亲和力。这些异构化合物的药理学特征非常有趣,因为它们的外周和中枢作用存在差异,
    DOI:
    10.1016/s0968-0896(98)00259-4
点击查看最新优质反应信息

文献信息

  • 3-arylcarbonyl-1-(C-attached-N-heteryl)-1H-indoles
    申请人:Sterling Drug Inc.
    公开号:US05068234A1
    公开(公告)日:1991-11-26
    2-R.sub.2 -R.sub.4 -substituted-3-R.sub.3 -CO-1-[(C-attached-N-herteryl)-(Alk).sub.n ]-1H-indoles useful as analgesic, anti-rheumatic, anti-inflammatory or anti-glaucoma agents.
    2-R.sub.2 -R.sub.4 -取代的-3-R.sub.3 -CO-1-[(C-连接的-N-杂环)-(Alk).sub.n ]-1H-吲哚可用作镇痛、抗风湿、抗炎或抗青光眼药剂。
  • Heterocyclic Compounds as Ccr2b antagonists
    申请人:Bower Justin Fairfield
    公开号:US20090099156A1
    公开(公告)日:2009-04-16
    Compounds of formula (I) Q-L-W—C(═X)-Z-P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.
    化合物的公式(I)Q-L-W—C(═X)-Z-P,其中Q是公式—N(R1)(R2)的胺基;L是烷基或杂环基烷基连接物;W是由环原子Y1和Y2组成的6-或7-成员脂肪环,其中Y1和Y2分别与基团L和C(X)连接,并且Y1和Y2分别独立地从N和C中选出;X是O、N、N—CN或S;Z是NR3;P是可选取代的单环或双环芳基或杂芳基基团;以及其药学上可接受的盐或溶剂,可用于治疗C-C趋化因子介导的疾病。
  • Heterocyclic Compounds as CCR2 Antagonists
    申请人:Bower Justin Fairfield
    公开号:US20120264762A1
    公开(公告)日:2012-10-18
    Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R 1 )(R 2 ); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y 1 and Y 2 which are linked to groups L and C(X) respectively and Y 1 and Y 2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR 3 ; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C—C chemokine mediated conditions.
    化合物的式子为(I)Q-L-W—C(═X)—Z—P,其中Q是公式—N(R1)(R2)的胺基;L是烷基或杂环烷基-烷基连接物;W是一个6-或7-成员的脂肪环,包括环原子Y1和Y2,它们分别与基团L和C(X)相连,Y1和Y2独立地选自N和C;X是O、N、N—CN或S;Z是NR3;P是一个可选择取代的单环或双环芳基或杂芳基基团;以及其药学上可接受的盐或溶剂,用于治疗C-C趋化因子介导的疾病。
  • Heterocyclic compounds as ccr2b antagonists
    申请人:AstraZeneca AB
    公开号:US07906645B2
    公开(公告)日:2011-03-15
    Compounds of formula (I) Q-L-W—C(═X)—Z—P wherein Q is an amine of the formula —N(R1)(R2); L is an alkyl or heterocyclyl-alkyl linker; W is a 6- or 7-membered aliphatic ring comprising ring atoms Y1 and Y2 which are linked to groups L and C(X) respectively and Y1 and Y2 are independently selected from N and C; X is O, N, N—CN or S; Z is NR3; P is an optionally substituted monocyclic or bicyclic aryl or heteroaryl group; and pharmaceutically acceptable salts or solvates thereof, are useful in the treatment of C-C chemokine mediated conditions.
    化合物的公式(I) Q-L-W—C(═X)—Z—P,其中Q是公式—N(R1)(R2)的胺基;L是烷基或杂环烷基-烷基连接物;W是一个6-或7-成员的脂肪环,包括环原子Y1和Y2,它们分别与基团L和C(X)连接,并且Y1和Y2是独立选择的N和C;X是O、N、N—CN或S;Z是NR3;P是可选择取代的单环或双环芳基或杂芳基基团;以及其药学上可接受的盐或溶剂,对于治疗C-C趋化因子介导的疾病是有用的。
  • NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF
    申请人:Kiyoto Taro
    公开号:US20100168418A1
    公开(公告)日:2010-07-01
    A nitrogen-containing heterocyclic compound represented by the general formula: wherein the dashed line represents a single bond or a double bond; R 1 , R 2 , R 3 , R 4 and R 5 independently represent a hydrogen atom, halogen atom, a lower alkyl, aryl, lower alkoxy or monocyclic heterocyclic group which may be substituted or the like; R 6 represents a lower alkyl, aryl, monocyclic heterocyclic, bicyclic heterocyclic or tricyclic heterocyclic group which may be substituted; X 1 represents a lower alkylene group or the like; X 2 represents a lower alkylene, lower alkenylene or lower alkynylene group which may be substituted; X 3 represents an oxygen atom, sulfur atom, a sulfinyl group, sulfonyl group or the like; Y 1 represents a bivalent cyclic group, containing a nitrogen, which may be substituted or the like; and Z 1 represents a nitrogen atom, a carbon atom which may be substituted or the like, or a salt thereof. The compound or salt has a potent antibacterial activity and a high safety, and is therefore useful as an excellent antibacterial agent.
    一种含氮杂环化合物,通式如下:其中虚线代表单键或双键;R1、R2、R3、R4和R5分别独立地代表氢原子、卤素原子、较低的烷基、芳基、较低的烷氧基或可以被取代的单环杂环基等;R6代表较低的烷基、芳基、单环杂环、双环杂环或三环杂环基,可以被取代;X1代表较低的烷基亚基或类似物;X2代表可以被取代的较低烷基、较低烯基或较低炔基亚基;X3代表氧原子、硫原子、亚砜基、磺酰基或类似物;Y1代表含有氮的二价环状基团,可以被取代或类似物;Z1代表氮原子、可以被取代的碳原子或类似物,或其盐。该化合物或盐具有强效的抗菌活性和高度的安全性,因此可用作优良的抗菌剂。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物